deltatrials
Completed PHASE4 NCT00295022

Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects

Double-blind, Three Parallel Randomized Groups, Therapeutic Confirmatory Clinical Trial to Compare the Efficacy of Oral Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit (EEU)

Sponsor: UCB S.A. - Pharma Sector

Conditions Rhinitis, Allergic, Seasonal
Interventions Levocetirizine Montelukast Placebo
Updated 8 times since 2017 Last updated: Aug 13, 2018 Started: Jul 29, 2006 Primary completion: Oct 1, 2006 Completion: Oct 1, 2006

Listed as NCT00295022, this PHASE4 trial focuses on Rhinitis, Allergic, Seasonal and remains completed. Sponsored by UCB S.A. - Pharma Sector, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Oct 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Aug 2018 — Oct 2018 [monthly]

    Completed PHASE4

▶ Show 3 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Completed PHASE4

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB S.A. - Pharma Sector
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Kingston, Canada